Revenue (Tables)

6 Months Ended

Jun. 30, 2026

Disaggregation of Revenue [Abstract]

Schedule of Revenue Disaggregated by Customer Type

The following table presents the Company's revenue disaggregated by customer type (in thousands):


		Three Months Ended June 30,								Six Months Ended June 30,
		2026				2025				2026				2025
Pharma testing services (1)		$	16,789			$	11,023			$	27,513			$	24,617
Enterprise sales			—				2,315				393				4,780
Population sequencing			3,000				3,308				5,500				7,521
Clinical diagnostic			2,541				469				3,972				777
Other			27				88				451				113
Total revenue		$	22,357			$	17,203			$	37,829			$	37,808

(1) Includes related party revenue of $8.4 million and $1.9 million for the three months ended June 30, 2026 and 2025, respectively, and $11.5 million and $2.4 million for the six months ended June 30, 2026 and 2025, respectively.

Schedule of Contract Assets and Liabilities

The opening and closing balances of receivables and contract liabilities from contracts with customers are shown below (in thousands). Contract assets were immaterial for all periods presented.


		June 30, 2026				December 31, 2025
Opening balances:
Accounts receivable, net		$	16,203			$	8,140

Short-term contract liabilities			1,562				3,100
Total contract liabilities			1,562				3,100

Closing balances:
Accounts receivable, net			15,102				16,203

Short-term contract liabilities			3,395				1,562
Total contract liabilities		$	3,395			$	1,562